Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, CMN SXXI-IMSS, Av, Cuauhtémoc 330, Col, Doctores, México, Distrito Federal 06720, México.
Infect Agent Cancer. 2012 Dec 3;7(1):34. doi: 10.1186/1750-9378-7-34.
Human Papillomavirus (HPV) in cervical epithelium has been identified as the main etiological factor in the developing of Cervical Cancer (CC), which has recently become a public health problem in Mexico. This finding has allowed for the development of vaccines that help prevent this infection. In the present study, we aimed to determine the prevalence and HPV type-distribution in Mexican women with CC, high-grade squamous intraepithelial lesion (HSIL), low-grade squamous intraepithelial lesion (LSIL), and Normal cytology (N) to estimate the impact of the HPV vaccines.
The PubMed database was used to identify and review all articles that reported data on HPV prevalence in CC, precursor lesions, and normal cytology of Mexican women.
A total of 8,706 samples of the tissues of Mexican women were stratified according to diagnosis as follows: 499 for CC; 364 for HSIL; 1,425 for LSIL, and 6,418 for N. According to the results, the most prevalent genotypes are the following: HPV16 (63.1%), -18 (8.6%), -58, and -31 (5%) for CC; HPV-16 (28.3%), 58 (12.6%), 18 (7.4%), and 33 (6.5%) for HSIL; HPV-16 (13.1%), 33 (7.4%), 18 (4.2%), and 58 (2.6%) for LSIL, and HPV-16 (3.4%), 33 (2.1%), 18, and 58 (1.2%) for N.
Taken together, genotypes 58 and 31 (10%) are more common than type 18 (8.6%) in CC. Therefore, the inclusion of these two genotypes in a second-generation vaccine would provide optimal prevention of CC in Mexico.
人乳头瘤病毒（HPV）在宫颈上皮中的存在已被确定为宫颈癌（CC）发展的主要病因，这在最近已成为墨西哥的一个公共卫生问题。这一发现促使开发了有助于预防这种感染的疫苗。在本研究中，我们旨在确定墨西哥 CC、高级别鳞状上皮内病变（HSIL）、低级别鳞状上皮内病变（LSIL）和正常细胞学（N）女性中 HPV 的流行率和 HPV 型分布，以评估 HPV 疫苗的影响。
使用 PubMed 数据库来识别和回顾所有报告墨西哥女性 CC、前体病变和正常细胞学中 HPV 流行率数据的文章。
根据诊断将总共 8706 例墨西哥女性组织样本分层如下：499 例 CC；364 例 HSIL；1425 例 LSIL 和 6418 例 N。根据结果，最常见的基因型如下：CC 为 HPV16（63.1%）、-18（8.6%）、-58 和-31（5%）；HSIL 为 HPV-16（28.3%）、58（12.6%）、18（7.4%）和 33（6.5%）；LSIL 为 HPV-16（13.1%）、33（7.4%）、18（4.2%）和 58（2.6%），N 为 HPV-16（3.4%）、33（2.1%）、18 和 58（1.2%）。
总的来说，基因型 58 和 31（10%）在 CC 中比 18 型（8.6%）更为常见。因此，在第二代疫苗中加入这两种基因型将为墨西哥提供 CC 的最佳预防效果。
